GE HealthCare Technologies Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | — | $20.63B | $19.67B | $19.60B | $18.34B | $17.61B |
| Imaging | — | — | — | $10.14B | $9.66B | $9.22B |
| Ultrasound | — | — | — | $3.52B | $3.42B | $3.31B |
| Patient Care Solutions | — | — | — | $3.13B | $2.83B | $2.83B |
| Pharmaceutical Diagnostics | — | — | — | $2.18B | $1.96B | $1.76B |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | $8.25B | $8.21B | $7.92B | $7.18B | $7.17B |
| Gross Margin | — | 40.0% | 41.7% | 40.4% | 39.1% | 40.7% |
| Operating Expenses | ||||||
| Research & Development | — | $1.26B | $1.31B | $1.21B | $1.03B | $816.0M |
| SG&A Expense | — | $4.23B | $4.27B | $4.28B | $3.63B | $3.56B |
| Operating Income | — | $2.76B | $2.63B | $2.44B | $2.52B | $2.80B |
| Operating Margin | — | 13.4% | 13.3% | 12.4% | 13.8% | 15.9% |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | — | $2.77B | $2.58B | $2.36B | $2.51B | $2.88B |
| Income Tax Expense | — | $614.0M | $531.0M | $743.0M | $563.0M | $600.0M |
| Net Income | — | $2.08B | $1.99B | $1.57B | $1.92B | $2.25B |
| Net Margin | — | 10.1% | 10.1% | 8.0% | 10.4% | 12.8% |
| EPS (Basic) | — | $4.56 | $4.37 | $3.05 | $4.22 | $4.95 |
| EPS (Diluted) | — | $4.55 | $4.34 | $3.03 | $4.22 | $4.95 |
| Shares Outstanding (Basic) | 455.7M | 456.0M | 456.0M | 455.0M | 454.0M | 454.0M |
| Shares Outstanding (Diluted) | 455.7M | 458.0M | 459.0M | 458.0M | 454.0M | 454.0M |
| Dividends Per Share | — | $0.14 | $0.13 | $0.12 | — | — |